NIH, industry in cancer immunotherapy partnership

On Thursday, NIH and 11 biopharma companies launched the Partnership for Accelerating Cancer Therapies (PACT), a $215 million public-private partnership designed to identify, validate and standardize biomarkers for cancer immunotherapies.

While immunotherapies have been highly successful in certain cancers such as melanoma, leukemia and lymphoma, it remains difficult to predict which individual patients will respond, and immunotherapies have not been effective against many solid tumors such as pancreatic, colon and breast cancers...